Miragen Therapeutics, Inc. (MGEN) EPS Estimated At $-0.29

July 14, 2018 - By Andrea Pope

Analysts expect Miragen Therapeutics, Inc. (NASDAQ:MGEN) to report $-0.29 EPS on August, 10.They anticipate $0.05 EPS change or 14.71 % from last quarter’s $-0.34 EPS. After having $-0.18 EPS previously, Miragen Therapeutics, Inc.’s analysts see 61.11 % EPS growth. The stock increased 2.95% or $0.21 during the last trading session, reaching $7.34. About 168,509 shares traded or 5.67% up from the average. Miragen Therapeutics, Inc. (NASDAQ:MGEN) has declined 34.18% since July 14, 2017 and is downtrending. It has underperformed by 46.75% the S&P500.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $221.61 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The company's clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More news for Miragen Therapeutics, Inc. (NASDAQ:MGEN) were recently published by: Nasdaq.com, which released: “miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201” on July 10, 2018. Investorplace.com‘s article titled: “10 Top Stock Ideas to Beat the Blues” and published on July 06, 2018 is yet another important article.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.